Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Grabar Law Office is actively investigating claims on behalf of MacroGenics, Inc. (NASDAQ: MGNX) shareholders. If you have ...
MacroGenics, Inc. (NASDAQ:MGNX – Free Report) – Investment analysts at B. Riley issued their FY2024 EPS estimates for shares ...
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The ...
Hosted on MSN6d
JMP Securities Downgrades MacroGenics (MGNX)Fintel reports that on November 7, 2024, JMP Securities downgraded their outlook for MacroGenics (NasdaqGS:MGNX) from Market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback